Testing a new low-temperature plasma treatment for cervical precancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new method using low-temperature argon plasma to treat cervical precancer (CIN 2) and compares it with the standard approach of active surveillance. If you have CIN 2 and are between 18 and 40 years old, this trial may offer an alternative to watching and waiting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 40 years old.
- You have been diagnosed with CIN 2 (moderate cervical precancer) confirmed by a biopsy.
- Your doctor can see the entire affected area during a colposcopy exam.
- You are not pregnant and do not plan to become pregnant in the next 6 months.
- You do not have other types of cervical precancer, severe infections, or serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a special light-based treatment (called HAL-PDT) for early cervical changes (CIN2) that were found on a recent biopsy. The goal is to see if this treatment can safely remove these changes and prevent them from becoming cancer.
This trial tests a shared decision-making approach for women newly diagnosed with cervical precancer (CIN2). It helps you and your doctor choose the best next step together.
This study tests a new tool called PreCursor-M+® to see how well it helps doctors manage CIN2, a moderate cervical cell change. It’s for people who have already been diagnosed with CIN2 and know their HPV test results.
This study tests a new non-invasive plasma treatment for cervical infections caused by high- and low-risk HPV types. It may help clear the virus and prevent related health issues.
This study tests a light-based treatment (photodynamic therapy) for cervical precancer called CIN2. It may be an option if you want to avoid surgery and preserve the cervix.
This trial tests a new way to quickly diagnose and treat cervical pre-cancer using a point-of-care device. It may help women who are HPV-positive avoid a separate treatment visit.
Hear when a new CIN2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.